# Study of Everolimus (RAD001) in Combination With Lenalidomide

> **NCT01218555** · PHASE1 · COMPLETED · sponsor: **Emory University** · enrollment: 44 (actual)

## Conditions studied

- Solid Organ Malignancies
- Adenoidcystic Carcinoma
- Neuroendocrine Tumors

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT01218555
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09-09
- **Primary completion:** 2020-11-05
- **Final completion:** 2020-11-05
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2022-01-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01218555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01218555, "Study of Everolimus (RAD001) in Combination With Lenalidomide". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01218555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*